 |
| Photo:www.investopedia.com |
Eli Lilly (LLY.N) announced on Thursday that its groundbreaking obesity drug achieved an impressive average weight loss of 26.6% across two late-stage trials. The studies involved patients who made intensive lifestyle changes or received continuous treatment with the drug before cessation.
Lilly's experimental drug,
known as Mounjaro or tirzepatide, is currently being tested in obese or
overweight patients without type 2 diabetes. If approved for obesity treatment,
this drug is projected to become a blockbuster product and a crucial growth
driver for Lilly.
The latest data provides Lilly
with a competitive edge in an increasingly crowded obesity treatment market,
which includes key rivals such as Novo Nordisk (NOVOb.CO), Pfizer (PFE.N), and
Amgen (AMGN.O), according to Cantor Fitzgerald analyst Louise Chen.
Following the data release,
shares of Danish drugmaker Novo Nordisk, which sells the obesity drug Wegovy,
saw some retracement in gains.
In the initial study, Lilly's
drug demonstrated an additional 21.1% average weight reduction after 12 weeks
of lifestyle changes, including a low-calorie diet and exercise, compared to
the placebo group.
The second study showed an
average weight loss of 21.1% with Lilly's drug compared to the placebo at the
end of a 36-week period.
Notably, patients continued to
experience an extra 6.7% weight loss in the second study at the conclusion of
the 88-week treatment period before discontinuing the drug.
Lilly reported that both
trials achieved their secondary objectives, and overall, the safety profile of
the drug remained consistent with previous studies.
In April, Lilly unveiled data
from a large trial showing that a high dose of the drug helped individuals with
type 2 diabetes who were also obese or overweight, resulting in a nearly 16%
reduction in their body weight.
Last year, the company
revealed that the drug, when administered to obese or overweight individuals
without diabetes, led to an impressive weight loss of 22.5%, equivalent to
approximately 52 pounds (24 kg).
The promising results of these
studies highlight the potential of Lilly's obesity drug as a groundbreaking
treatment for weight loss, offering hope to countless individuals struggling
with obesity and its related health concerns. As the drug progresses through
the approval process, it may revolutionize the landscape of obesity treatment
and significantly impact the healthcare industry.
Posting Komentar untuk "Lilly's Obesity Drug Demonstrates Remarkable 26% Weight Loss in New Studies"